Format

Send to

Choose Destination
Clin Transl Sci. 2018 Jan;11(1):21-27. doi: 10.1111/cts.12500. Epub 2017 Oct 23.

Future of Rare Diseases Research 2017-2027: An IRDiRC Perspective.

Author information

1
National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), Bethesda, Maryland, USA.
2
IRDiRC Scientific Secretariat, Inserm-US14, Rare Diseases Platform, Paris, France.
3
Orphanet, Inserm-US14, Rare Diseases Platform, Paris, France.
4
Agence Nationale de la Recherche (ANR), Paris, France.
5
Shire, Lexington, Massachusetts, USA, (until April 2017).
6
Genetic Alliance, Washington DC, USA.
7
EURORDIS-Rare Diseases Europe, Paris, France.
8
Corporate Drug Development, Chiesi Farmaceutici S.p.A., Italy.
9
Children's Hospital of Eastern Ontario Research Institute, University of Ottawa, Ottawa, Canada.
10
Genetic Services of Western Australia, King Edward Memorial Hospital, Perth, Australia.
11
Western Australian Register of Developmental Anomalies, Perth, Australia.
12
National Centre for Rare Diseases, Istituto Superiore di Sanità, Rome, Italy.
13
Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK.
14
Japan Agency for Medical Research and Development (AMED), Tokyo, Japan.
15
Sanofi Genzyme, Cambridge, Massachusetts, USA.
16
Directorate General for Research and Innovation (DG RTD), European Commission, Brussels, Belgium, (until April 2017).
17
Merck & Co. Inc., Upper Gwynedd, Pennsylvania, USA, (from June 2017).
18
National Human Genome Research Institute (NHGRI), National Institutes of Health (NIH), Bethesda, Maryland, USA.
19
Office of Population Health Genomics, Public Health Division, Department of Health, Government of Western Australia, Perth, Australia.
PMID:
28796445
PMCID:
PMC5759721
DOI:
10.1111/cts.12500
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center